Cited by 194Dementia and Cognitive Impairment ResearchMedical Imaging Techniques and ApplicationsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Impact of molecular imaging on the diagnostic process in a memory clinic

Open access

Ossenkoppele, Rik, Prins, Niels D., Pijnenburg, Yolande A.L., Lemstra, Afina W., van der Flier, Wiesje M., Adriaanse, Sofie F., Windhorst, Albert D., Handels, Ron L.H., Wolfs, Claire A.G., Aalten, Pauline, Verhey, Frans R.J., Verbeek, Marcel M., van Buchem, Mark A., Hoekstra, Otto S., Lammertsma, Adriaan A., Scheltens, Philip, van Berckel, Bart N.M.·2013·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2012.07.003

Open this paper in CoChat — free account Open PDF

Abstract

Background: [ 11 C]Pittsburgh compound B ([ 11 C]PIB) and [ 18 F]‐2‐fluoro‐2‐deoxy‐D‐glucose ([ 18 F]FDG) PET measure fibrillar amyloid‐β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population. Methods: One hundred fifty‐four patients underwent paired dynamic [ 11 C]PIB and static [ 18 F]FDG PET scans shortly after completing a standard dementia screening. Two‐year clinical follow‐up data were available for 39 patients. Parametric PET images were assessed visually and results were reported to the neurologists responsible for the initial diagnosis. Outcome measures were (change in) clinical diagnosis and confidence in that diagnosis before and after disclosing PET results. Results: [ 11 C]PIB scans were positive in 40 of 66 (61%) patients with a clinical diagnosis of Alzheimer's disease (AD), 5 of 18 (28%) patients with frontotemporal dementia (FTD), 4 of 5 (80%) patients with Lewy body dementia, and 3 of 10 (30%) patients with other dementias. [ 18 F]FDG uptake patterns matched the clinical diagnosis in 38 of 66 (58%) of AD patients, and in 6 of 18 (33%) FTD patients. PET results led to a change in diagnosis in 35 (23%) patients. This only occurred when prior diagnostic certainty was <90%. Diagnostic confidence increased from 71 ± 17% before to 87 ± 16% after PET ( p < .001). Two‐year clinical follow‐up ( n = 39) showed that [ 11 C]PIB and [ 18 F]FDG predicted progression to AD for patients with mild cognitive impairment, and that the diagnosis of dementia established after PET remained unchanged in 96% of patients. Conclusions: In a memory clinic setting, combined [ 11 C]PIB and [ 18 F]FDG PET are of additional value on top of the standard diagnostic work‐up, especially when prior diagnostic confidence is low.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.07.003

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citation
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citation
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citation
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop*
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 101–194 of 194

The interest of amyloid PET imaging in the diagnosis of Alzheimerʼs disease
Vandenberghe, R. R., Adamczuk, K., & Laere, K. V. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000036 · Cited by 20
A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice
Kim, Y., Rosenberg, P., & Oh, E. S. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000492151 · Cited by 11
Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes
Bergeron, D., Beauregard, J.-M., Guimond, J., Fortin, M.-P., Houde, M., Poulin, S., Verret, L., Bouchard, R. W., & Laforce, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150302 · Cited by 17
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
Reimand, J., Groot, C., Teunissen, C. E., Windhorst, A. D., Boellaard, R., Barkhof, F., Nazarenko, S., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190836 · Cited by 16
Self-citation
Evaluation of Cognitive Impairment in Older Adults
Scharre, D. W., & Trzepacz, P. T. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.4.482 · Cited by 17
Utility of Easy Z-Score Imaging System-Assisted SPECT in Detecting Onset Age-Dependent Decreases in Cerebral Blood Flow in the Posterior Cingulate Cortex, Precuneus, and Parietal Lobe in Alzheimer’s Disease with Amyloid Accumulation
Hayashi, H., Kobayashi, R., Kawakatsu, S., Morioka, D., & Otani, K. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000507654 · Cited by 16
Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer’s Disease and Other Dementias
Bao, Y., Chau, A. C. M., Chiu, P. K., Shea, Y. F., Kwan, J. S. K., Chan, F. H. W., & Mak, H. K. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200890 · Cited by 15
Willingness to Undergo a Risky Treatment to Improve Cognition Among Persons With Cognitive Impairment Who Received an Amyloid PET Scan
Jutkowitz, E., Houtven, C. H. V., Plassman, B. L., & Mor, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000338 · Cited by 15
Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
Fernández-Gómez, F.-J., Tran, H., Dhaenens, C., Caillet‐Boudin, M., Schraen‐Maschke, S., Blum, D. L., Sablonnière, B., Buée‐Scherrer, V., Buée, L., & Sergeant, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_17 · Cited by 15
An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy
Firbank, M., Lloyd, J. J., Williams, D., Barber, R., Colloby, S. J., Barnett, N. A., Olsen, K., Davison, C. M., Donaldson, C., Herholz, K., et al. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.160804 · Cited by 15
Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment
Wang, Y., Lou, F., Li, Y., Liu, F., Wang, Y., Cai, L., Gordon, M. L., Zhang, Y., & Zhang, N. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211001113349 · Cited by 14
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine
Booij, J., Arbizu, J., Darcourt, J., Hesse, S., Nobili, F. M., Payoux, P., Pappatà, S., Tatsch, K., Walker, Z., & Pagani, M. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2415-x · Cited by 13
Clinical impact of 11 C ‐Pittsburgh compound‐ B positron emission tomography carried out in addition to magnetic resonance imaging and single‐photon emission computed tomography on the diagnosis of A lzheimer's disease in patients with dementia and mild cognitive impairment
Omachi, Y., Ito, K., Arima, K., Matsuda, H., Nakata, Y., Sakata, M., Sato, N., Nakagome, K., & Motohashi, N. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12326 · Cited by 13
Concordance Between 11 C-PIB-PET and Clinical Diagnosis in a Memory Clinic
Patricio, C. M., Cohen, G., Russo, J., Suarez, M. F., Nahas, F., Russo, G., Claudio, W., Santiago, P., Leonardo, T., Jorge, C., et al. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515576387 · Cited by 13
Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI
Tripathi, M., Tripathi, M., Parida, G., Kumar, R., Dwivedi, S. N., Nehra, A., & Bal, C. (2019) · Neurology India · doi:10.4103/0028-3886.271245 · Cited by 14
Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
Cheng, Y., Ren, J.-R., Jian, J.-M., He, C.-Y., Xu, M., Zeng, G., Tan, C., Shen, Y., Jin, W., Chen, D., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01962-6 · Cited by 11
Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer’s disease
Gjerum, L., Andersen, B. B., Bruun, M., Simonsen, A. H., Henriksen, O. M., Law, I. G., Hasselbalch, S. G., & Frederiksen, K. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248413 · Cited by 12
Anomaly detection for the individual analysis of brain PET images
Burgos, N., Cardoso, M. J., Samper‐Gonzàlez, J., Habert, M., Durrleman, S., Sebastien Ourselin, A., & Colliot, O. (2021) · Journal of medical imaging · doi:10.1117/1.jmi.8.2.024003 · Cited by 12
Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials
Rahman‐Filipiak, A., Bolton, C. J., Grill, J. D., Rostamzadeh, A., Chin, N. A., Heidebrink, J. L., Getz, S. J., Fowler, N. R., Rosen, A. C., Lingler, J. H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13380 · Cited by 11
Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN
Arbizu, J., García‐Ribas, G., Carrió, I., Garrastachu, P., Martínez‐Lage, P., & Molinuevo, J. L. (2015) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2015.05.004 · Cited by 11
Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis
Mishima, A., Nihashi, T., Ando, Y., Kawai, H., Kato, T., Ito, K., & Terasawa, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150675 · Cited by 10
The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit
Kim, H. J., Park, J., Jung, K. S., Kim, J., Jang, J. S., Kwon, S., Byun, M. S., Yi, D., Byeon, G., Jung, G., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00638-3 · Cited by 13
A novel approach to resilience and its links with education and Alzheimer's disease genetics
Carrigan, M., Bocancea, D. I., Vogel, J. W., van Loenhoud, A. C., Tesi, N., Barkhof, F., Lucassen, P. J., van der Flier, W. M., Krugers, H. J., van der Lee, S. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70379 · Cited by 9
Self-citation
The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic
Liu, F., Shi, Y., Wu, Q., Chen, H., Wang, Y., Cai, L., & Zhang, N. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14418 · Cited by 9
Reduced thiamine is a predictor for cognitive impairment of cerebral infarction
Feng, L., He, W., Huang, G., Lin, S., Yuan, C., Cheng, H., He, J., & Liu, Y. (2020) · Brain and Behavior · doi:10.1002/brb3.1709 · Cited by 9
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01474-z · Cited by 9
Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging
Mustafa, R., Brosch, J. R., Rabinovici, G. D., Dickerson, B. C., Carrillo, M. C., Glazier, B. S., Gao, S., Tierney, M., Fargo, K. N., Austrom, M. G., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000220 · Cited by 8
A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET/CT
Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Martínez‐Rodríguez, I., Martínez‐Amador, N., Sánchez-Salmón, A., la Fuente-Gómez, F. D., Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., & Banzo, I. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001004 · Cited by 8
Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
Triviño‐Ibáñez, E. M., Sánchez-Vañó, R., Sopena‐Novales, P., Romero-Fábrega, J. C., Rodrı́guez-Fernández, A., Pardo, C. C., Lozano, M. D., & Gómez-Río, M. M. (2019) · Medicine · doi:10.1097/md.0000000000016509 · Cited by 8
Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer’s Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins
Manca, C., Hopes, L., Kearney‐Schwartz, A., Roch, V., Karcher, G., Baumann, C., Marie, P., Malaplate, C., Jonveaux, T., & Verger, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181146 · Cited by 8
Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Antelmi, L., Pievani, M., Tarallo, A., Muscio, C., Guerra, U. P., Paghera, B., et al. (2016) · Neurodegenerative Diseases · doi:10.1159/000439255 · Cited by 7
Perspectives of the European Association of Nuclear Medicine (EANM) on early perfusion imaging in the context of amyloid PET imaging protocols
Morbelli, S. D., Weehaeghe, D. V., Verger, A., Tolboom, N., Fernandez, P. A., Brendel, M., Guedj, É., Garibotto, V., Cecchin, D., Yakushev, I. Y., et al. (2025) · The EANM Journal · doi:10.1016/j.eanmj.2025.100005 · Cited by 7
How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?
Chételat, G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.006 · Cited by 7
Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease
Aye, W. W. T., Stark, M. R., Horne, K., Livingston, L., Grenfell, S., Myall, D. J., Pitcher, T. L., Almuqbel, M. M., Keenan, R. J., Meissner, W. G., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12601 · Cited by 7
The impact of regional 99mTc-HMPAO single-photon-emission computed tomography (SPECT) imaging on clinician diagnostic confidence in a mixed cognitive impairment sample
Prosser, A. M. J., Tossici-Bolt, L., & Kipps, C. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.04.016 · Cited by 7
Re-Evaluation of Clinical Dementia Diagnoses with Pittsburgh Compound B Positron Emission Tomography
Gunnarsson, M. D., Lindau, M. P., Santillo, A. F., Wall, A., Engler, H., Lannfelt, L., Basun, H., & Kilander, L. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000356273 · Cited by 7
Amyloid Imaging in Dementia: Contribution or Confusion?
Frey, K. A. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.151571 · Cited by 7
Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients
Jiménez-Bonilla, J. F., Banzo, I., de Arcocha-Torres, M., Quirce, R., Martínez‐Rodríguez, I., Lavado-Pérez, C., Bravo-Ferrer, Z., Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., & CARRIL, J. M. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000569 · Cited by 7
Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease
Thientunyakit, T., Sethanandha, C., Muangpaisan, W., Chawalparit, O., Arunrungvichian, K., Siriprapa, T., Thongpraparn, T., Chanachai, R., & Gelovani, J. G. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000787 · Cited by 7
Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer’s disease
Bacci, J. R., Karagianni, S., Alexopoulou, Z.-S., Moukaled, S., Tato-Fernández, C., Arunachalam, P., Aslanyan, A., Aye, S., Rocha, A. S. L., Crugel, M., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01921-5 · Cited by 8
Role of Neurocellular Endoplasmic Reticulum Stress Response in Alzheimer’s Disease and Related Dementias Risk
Aceves, M., Granados, J., Leandro, A. C., Peralta, J. M., Glahn, D. C., Williams‐Blangero, S., Curran, J. E., Blangero, J., & Kumar, S. (2024) · Genes · doi:10.3390/genes15050569 · Cited by 7
Current role of 18F-FDG-PET in the differential diagnosis of the main forms of dementia
Guillén, E. F., Rosales, J. J., Coscia, D. L., Grisanti, F., Riverol, M., & Arbizu, J. (2020) · Clinical and Translational Imaging · doi:10.1007/s40336-020-00366-0 · Cited by 6
Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
Vives‐Rodriguez, A., Schiloski, K. A., Marín, A., Wang, R. Z., Hajos, G. P., Powsner, R. A., DeCaro, R. E., Budson, A. E., & Turk, K. W. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12320 · Cited by 6
The use of amyloid imaging in clinical praxis: a critical review
Nordberg, A. K. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0100-8 · Cited by 7
Clinical Assessment of Amyloid Imaging in Alzheimer's Disease: A Systematic Review of the Literature
Wahlster, P., Niederländer, C., Kriza, C., Schaller, S., & Kolominsky‐Rabas, P. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000351679 · Cited by 8
The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study
Vermeiren, M. R., Somsen, J. F., Luurtsema, G., Reesink, F. E., Verwey, N. A., Hempenius, L., Tolboom, N., Biessels, G. J., Biesbroek, J. M., Vernooij, M. W., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01588-4 · Cited by 5
Self-citation
A Comparison of Clinical Diagnostic Classification Criteria Used in Longitudinal Cohort Studies of the Alzheimer’s Disease Continuum: A Systematic Review
Villalpando, J. M., Leclerc, B., Le, M. T., Hudon, C., Bolduc, A., & Kergoat, M. (2025) · Neuropsychology Review · doi:10.1007/s11065-025-09663-9 · Cited by 6
Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations
Park, K. H., Choi, S. H., Shim, Y., Youn, Y. C., Yang, D. W., & Kim, S. (2025) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0037 · Cited by 6
Cerebral Amyloid Positivity Prediction Models Using Clinical Data in Subjects With Mild Cognitive Impairment and Dementia
Joo, S. H., & Lee, C. U. (2021) · Psychiatry Investigation · doi:10.30773/pi.2021.0104 · Cited by 5
Double-Edged Sword: A Positive Brain Scan Result Heightens Confidence in an Alzheimer’s Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette-Based Experiment
Stites, S. D., Lee, B. N., Largent, E. A., Harkins, K. A., Sankar, P. L., Krieger, A. Μ., & Brown, R. T. (2024) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbae109 · Cited by 5
Diagnostic de la maladie d’Alzheimer : apport de l’imagerie au florbétapir et autres radiopharmaceutiques de la plaque amyloïde
Semah, F., Deberdt, W. G., & Ceccaldi, M. P. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2016.08.001 · Cited by 5
Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units
Lage, C., González‐Suárez, A., Pozueta, A., Riancho, J., Kazimierczak, M., Bravo, M., Jiménez-Bonilla, J. F., Torres, M. D. A., Quirce, R., Banzo, I., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170985 · Cited by 5
The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice
Spallazzi, M., Barocco, F., Michelini, G., Morelli, N., Scarlattei, M., Baldari, G., Ruffini, L., & Caffarra, P. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180646 · Cited by 5
Brain 18 F ‐fluorodeoxyglucose positron emission tomography: An efficient tool at the initial diagnosis of nonlesional late onset epilepsy
Puisieux, S., Heyer, S., Forthoffer, N., Doyen, M., Tyvaert, L., & Verger, A. (2025) · Epilepsia · doi:10.1111/epi.18328 · Cited by 4
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country
Damián, A., Portugal, F., Niell, N., Quagliata, A., Bayardo, K., Alonso, Ó., & Ferrando, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.630958 · Cited by 4
Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
Venkataraman, A. V., Bai, W., Whittington, A., Myers, J. F., Rabiner, E. A., Lingford-Hughes, A. R., Matthews, P. M., & Initiative, A. D. N. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00910-8 · Cited by 4
Utility of Amyloid PET Scans in the Evaluation of Patients Presenting with Diverse Cognitive Complaints
Shea, Y. F., Barker, W., Greig-Gusto, M. T., Loewenstein, D., DeKosky, S. T., & Duara, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180683 · Cited by 3
How Many Alzheimer–Perusini’s Atypical Forms Do We Still Have to Discover?
Donato, L., Mordà, D., Scimone, C., Alibrandi, S., D’Angelo, R., & Sidoti, A. (2023) · Biomedicines · doi:10.3390/biomedicines11072035 · Cited by 3
Visual Rating and Computer-Assisted Analysis of FDG PET in the Prediction of Conversion to Alzheimer’s Disease in Mild Cognitive Impairment
Kang, J. M., Lee, J., Kim, Y. K., Sohn, B. K., Byun, M. S., Choi, J., Son, S. K., Im, H. J., Ryu, Y. H., Ryu, Y. H., et al. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0334-z · Cited by 3
An online vignette study of diagnostic testing: Racial and ethnic differences in Alzheimer's disease diagnosis confidence and stigma
Stites, S. D., Lee, B. N., Kuz, C., Adams, M., Harkins, K. A., Xie, S. X., Walke, L. M., Sankar, P. L., & Hamilton, R. H. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70178 · Cited by 2
Association between results of an amyloid PET scan and healthcare utilization in individuals with cognitive impairment
Jutkowitz, E., Shewmaker, P., Ford, C. B., Smith, V. A., O'Brien, E. C., Shepherd‐Banigan, M. E., Bélanger, E., Plassman, B. L., Burke, J. R., Houtven, C. H. V., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18696 · Cited by 2
Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment
Mimenza-Alvarado, A. J., León-Del-Ángel Karen, G., Rodrigo, H.-R., Rodríguez-Callejas, J. D., Yeverino-Castro, S. G., & Aguilar-Navarro, S. G. (2024) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.24000161 · Cited by 1
Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings
Ossenkoppele, R., Booij, J., Scheltens, P., & van Berckel, B. N. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_9 · Cited by 1
Self-citation
Möglichkeiten moderner Bildgebungstechnologien im Rahmen der Frühdiagnostik von Alzheimererkrankung
Unschuld, P. G. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000674 · Cited by 1
The Impact of β-amyloid Positron Emission Tomography On the Diagnostic and Treatment Decisions of Dementia Experts
Ganz, M. L., Tawah, A. F., Guo, S., Chitnis, A. S., Silies, H., Schäuble, B., Jovalekic, A., & Foster, N. L. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0059 · Cited by 1
Criterios diagnósticos en la enfermedad demencial ¿Qué hay de nuevo?
Labos, E., Bavec, C. V., Cristalli, D. O., Deschle, F., Isaac, C. F., Dorman, G. S., Ollari, J., Rubiño, V., & Russo, M. J. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.460 · Cited by 4
Utilidad de la neuroimagen amiloidea en Neurología asistencial
Méndez, P. C., Cohen, G., Russo, M. J., Suarez, M. F., Nahas, F., Russo, G., Claudio, W., Paz, S., Leonardo, T., Campos, J., et al. (2014) · Neurología Argentina · doi:10.1016/j.neuarg.2014.02.003 · Cited by 1
IC‐P‐007: Clinical utility of amyloid imaging in the differential diagnosis of atypical/unclear dementias and its impact on caregivers
Bensaïdane, M. R., Bouchard, R. W., Fortin, M., Houde, M., Rosa‐Neto, P., Poulin, S. P., Verret, L., Soucy, J., Beauregard, J., & Laforce, R. J. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.027 · Cited by 1
18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease
Capitanio, S., Bauckneht, M., Arnaldi, D., Massa, F., Meli, R., Ceriani, V., Nobili, F. M., & Morbelli, S. D. (2019) · Springer eBooks · doi:10.1007/978-3-030-01523-7_5 · Cited by 1
Amyloid Imaging
Shaikh, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-9535-3_13 · Cited by 1
Health technology assessment of diagnostic strategies for Alzheimer’s disease
Handels, R. L. H. (2014) · Research Publications (Maastricht University) · doi:10.26481/dis.20140911rh · Cited by 1
Self-citation
Biomarkers as Monitors of Drug Effect, Diagnostic Tools and Predictors of Deterioration Rate in Alzheimer’s Disease
Gunnarsson, M. D. (2013)
The Path of Alzheimer’s disease
Jansen, W. J. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161125wj
Neuroimaging Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations
Witte, M. M., Foster, N. L., Fleisher, A., Williams, M., Quaid, K. A., Wasserman, M. R., Hunt, G., Roberts, J. S., Rabinovici, G. D., Levenson, J. L., et al. (2015)
Astrocyte-specific druggable protein as PET-ligand target for early detection of Alzheimer's disease
Sjöberg, R. (2017) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Neuroimaging in Dementia
Ong, K. T. (2018) · OBM Geriatrics · doi:10.21926/obm.geriatr.1803011
Diagnostiek van de ziekte van Alzheimer
van der Flier, W. M. (2018) · Neuropraxis · doi:10.1007/s12474-018-00205-z
Amyloid-β PET Imaging in Aging and Dementia
Tolboom, N., Ossenkoppele, R., & van Berckel, B. N. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-01523-7_11
Self-citation
PET and CSF amyloid-β status are differently predicted by patient features: Information from discordant casesPreprint
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/673467
Self-citation
Added diagnostic accuracy after [18F]flutemetamol PET scanning in young patients with dementia in an academic memory clinic settingPreprint
Handels, R. L. H., Zwan, M. D., Pelkmans, W., Biessels, G. J., van Domburg, P., Hoff, E. I., Roks, G., Schoonenboom, N. S. M., Verweij, N., van Berckel, B. N. M., et al. (2021) · medRxiv · doi:10.1101/2021.11.30.21266815
Self-citation
Amyloid Tracers
Nordberg, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00071-3
Novel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use
Janssen, O. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220617oj
Investigation of Electrical Properties of Iron Oxide Nanoparticles Bonded with Ionic Solutions for Microwave Ablation Systems
Murat, C., Kaya, A., Keseli, E., Kuruş, M., Uzun, S. D., Can, M., & Erdoğan, M. A. (2023) · International Journal of Emerging Multidisciplinaries Engineering · doi:10.54938/ijemd-engr.v1i1.2
Psicosis tardías y fenocopias
Ollari, J., Deschle, F., Rubiño, V., Blanco, R., Ciufia, N., & Delembert, W. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i161.487
The role of diabetes and vascular burden in Alzheimer’s disease
van Gils, V. (2024) · doi:10.26481/dis.20240628vg
Functional Neuroimaging in Nuclear Medicine
Dizdar, N. A., & Cayir, D. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009689
How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil
Macêdo, L. C. D. A., de Campos, R. B., Nunes, L. E. D. B., Pinheiro, M. G. M., da Silva, A. H. T. T., Leão, M. R. V. C., Silva, A. D. S., Mourato, F. A., Brandão, S. C. S., & Barbosa, B. J. A. P. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1808086
Additional file 1 of [11C]PIB amyloid quantification: effect of reference region selection
Heeman, F., Hendriks, J., Lopes Alves, I., Ossenkoppele, R., Tolboom, N., van Berckel, B. N. M., Lammertsma, A. A., & Yaqub, M. M. (2020) · Figshare · doi:10.6084/m9.figshare.13114872
Self-citation
Additional file 1 of Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
Venkataraman, A. V., Bai, W., Whittington, A., Myers, J. F., Rabiner, E. A., Lingford-Hughes, A. R., & Matthews, P. M. (2021) · Figshare · doi:10.6084/m9.figshare.16986634
Additional file 1 of Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans
Moon, S., Kim, S., Mankhong, S., Choi, S. H., Vandijck, M. L. J., Kostanjevečki, V., Jeong, J. H., Yoon, S. J., Park, K. W., Kim, E.-J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13565702
Additional file 3 of Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
Venkataraman, A. V., Bai, W., Whittington, A., Myers, J. F., Rabiner, E. A., Lingford-Hughes, A. R., & Matthews, P. M. (2021) · Figshare · doi:10.6084/m9.figshare.16986640
Additional file 1 of Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Figshare · doi:10.6084/m9.figshare.25802834
Additional file 2 of Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support
Venkataraman, A. V., Bai, W., Whittington, A., Myers, J. F., Rabiner, E. A., Lingford-Hughes, A. R., & Matthews, P. M. (2021) · Figshare · doi:10.6084/m9.figshare.16986637
Diagnosis of neurodegenerative diseases based on molecular imaging
Quan, L., Lang, M., Yue, J., Zhu, J., Xu, J., Wang, K., Huang, H., Song, Q., Zhao, Y., Zhu, Z., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180865

Authors: Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., Verhey, F. R. J., Verbeek, M. M., van Buchem, M. A., Hoekstra, O. S., Lammertsma, A. A., Scheltens, P., & van Berckel, B. N. M.
Affiliations: Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Maastricht University Medical Centre (NL)
Radboud University Medical Center (NL)
Leiden University Medical Center (NL)
Corresponding author: Ossenkoppele, Rik
ORCID: Ossenkoppele, Rik
Prins, Niels D.
Pijnenburg, Yolande A.L.
Lemstra, Afina W.
van der Flier, Wiesje M.
Windhorst, Albert D.
Handels, Ron L.H.
Wolfs, Claire A.G.
Verhey, Frans R.J.
Verbeek, Marcel M.
van Buchem, Mark A.
Hoekstra, Otto S.
Lammertsma, Adriaan A.
Scheltens, Philip
van Berckel, Bart N.M.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2012-11-19
Volume: 9
Issue: 4
Pages: 414-421
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2012.07.003
OpenAlex: W2137348301
Cited by: 194
References: 37
Citations by year: 2026: 2 · 2025: 9 · 2024: 8 · 2023: 10 · 2022: 7 · 2021: 19 · 2020: 16 · 2019: 21 · 2018: 20 · 2017: 18 · 2016: 16 · 2015: 26 · 2014: 12 · 2013: 10
FWCI: 10.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Research Publications (Maastricht University) (submittedVersion, other-oa)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Funders: Center for Translational Molecular Medicine (02N-101)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: amyloid PET, Pittsburgh compound B
MeSH terms: Aged, Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Dementia, Diagnosis, Differential, Female, Fluorine Radioisotopes, Follow-Up Studies, France, Humans, Male, Memory Disorders, Middle Aged, Outpatient Clinics, Hospital, Prospective Studies, Sensitivity and Specificity, Thiazoles, Treatment Outcome, Disease Progression, Radiopharmaceuticals, Fluorodeoxyglucose F18, Lewy Body Disease, Early Diagnosis, Positron-Emission Tomography, Molecular Imaging, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of molecular imaging on the diagnostic process in a memory clinic

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks